share_log

Brookline Capital Initiates Coverage On Quince Therapeutics With Buy Rating, Announces Price Target of $9

Benzinga ·  Dec 18 20:48  · Ratings

Brookline Capital analyst Kumaraguru Raja initiates coverage on Quince Therapeutics (NASDAQ:QNCX) with a Buy rating and announces Price Target of $9.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment